Plasmacytoid variant of bladder cancer is a histological factor of extremely unfavorable prognosis of recurrence-free and cancer-specific survival in organ-preserving surgical treatment of bladder cancer: clinical observations of 4 patients

Authors

DOI:

https://doi.org/10.14739/2310-1237.2026.1.335238

Keywords:

bladder cancer, invasive cancer, urothelial carcinoma, histology, plasmacytoid carcinoma, survival, recurrence, metastatic, radical cystectomy

Abstract

Organ-sparing surgical treatment of muscle-invasive bladder cancer is considered a treatment of choice in carefully selected patients, as it can provide satisfactory survival rates and high quality of life due to preservation of the bladder. However, there is a group of patients who, while meeting the criteria for bladder resection, have an extremely poor prognosis in terms of overall (OS), relapse-free (RFS) and progression-free survival (PFS) due to a certain histological variants of bladder cancer, which necessitates immediate radical cystectomy.

Aim: to investigate the impact of the plasmacytoid variant of urothelial carcinoma of the bladder on both OS, RFS, and PFS rates, and on the tactics of radical treatment of patients with organ-confined bladder cancer who were candidates for organ-sparing treatment at initial presentation.

Materials and methods. The medical records of 215 patients with bladder cancer who underwent surgery between 2020–2025 at the Center for Urology and Urological Oncology of the Feofaniya Clinical Hospital of the State Administration of Affairs were retrospectively analyzed. Among them, we selected patients who harbored elements of plasmacytoid differentiation of urothelial carcinoma in primary transurethral resection of a bladder (TURB) specimen, which has been confirmed by immunohistochemical staining. As a control for assessing survival rates using Kaplan–Meier analysis, an identical number of patients with pure urothelial carcinoma of identical stages, age, gender, and primary treatment tactics who had local recurrence after TURB was selected.

Results. The prevalence of plasmacytoid urothelial carcinoma (PVUC) among our patients with bladder cancer was 1.86 %, or 4 patients. The mean age of the patients was 53.5 ± 10.3 years, and 50 % were men. All survival rates after organ-preserving treatment in the scope of TURB were significantly worse for patients with plasmacytoid urothelial carcinoma compared with pure urothelial carcinoma. The median OS, RFS, and PFS for PVUC were 6 months (p = 0.0177), 1.5 months (p = 0.0067), and 4.5 months (p = 0.0207), respectively. For pure urothelial carcinoma, the median RFS was 17 months, and the median PFS and OS were not reached. In patients with PVUC who underwent emergency radical cystectomy for local recurrence, the median OS, RFS, and PFS were not reached at 12 months of follow-up.

Conclusions. Plasmacytoid variant of urothelial carcinoma is a factor of extremely unfavorable prognosis of overall, relapse-free and progression-free survival of patients after organ-sparing treatment of bladder cancer, compared with pure urothelial carcinoma. Detection of plasmacytoid variant in a biopsy of bladder cancer requires the fastest possible radical cystectomy in order to ensure the best overall survival rates.

Author Biographies

P. H. Yakovlev, National Scientific Center of Surgery and Transplantation Named after O. O. Shalimov of the National Academy of Medical Sciences of Ukraine, Kyiv

MD, PhD, DSc, Head of the Department of Kidney Transplantation

L. H. Rosha, Feofaniya Clinical Hospital of the State Administration of Affairs, Kyiv

MD, PhD, DSc, Professor, Head of the Center of Pathological Anatomy and Cytomorphology

References

  1. Alfred Witjes J, Max Bruins H, Carrión A, Cathomas R, Compérat E, Efstathiou JA, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol. 2024;85(1):17-31. doi: https://doi.org/10.1016/j.eururo.2023.08.016
    | |
  2. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, et al. Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(4):216-25. doi: https://doi.org/10.6004/jnccn.2024.0024
    | |
  3. Hamad J, McCloskey H, Milowsky MI, Royce T, Smith A. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. Int Braz J Urol. 2020;46(2):169-84. doi: https://doi.org/10.1590/s1677-5538.ibju.2020.99.01
    | |
  4. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(3):329-54. doi: https://doi.org/10.6004/jnccn.2020.0011
    | |
  5. Maarouf AM, Khalil S, Salem EA, ElAdl M, Nawar N, Zaiton F. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. BJU Int. 2011;107(10):1605-10. doi: https://doi.org/10.1111/j.1464-410X.2010.09564.x
    | |
  6. Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75-94. doi: https://doi.org/10.1016/j.eururo.2021.08.010
    | |
  7. Netto GJ, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82(5):469-82. doi: https://doi.org/10.1016/j.eururo.2022.07.002
    | |
  8. van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Compérat E, Dimitropoulos K, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. Eur Urol. 2025;87(5):582-600. doi: https://doi.org/10.1016/j.eururo.2025.02.019
    | |
  9. Soave A, Schmidt S, Dahlem R, Minner S, Engel O, Kluth LA, et al. Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol. 2015;33(1):21.e1-.e9. doi: https://doi.org/10.1016/j.urolonc.2014.10.013
    | |
  10. Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Zhang L, et al. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017;147(5):500-6. doi: https://doi.org/10.1093/ajcp/aqx029
    | |
  11. Benabdallah W, Ben Othmane M, Ouahchi I, Mestiri S, Belkacem O, Bouassida K, et al. Plasmacytoid bladder cancer: a rare case report. Ann Med Surg (Lond). 2023;85(5):1885-7. doi: https://doi.org/10.1097/MS9.0000000000000374
    |
  12. Shimizu N, Moritoki Y, Katsumi N, Yanase T, Sugino T, Kanemoto K, et al. Plasmacytoid Urothelial Carcinoma of the Bladder That Manifests Disseminated Carcinomatosis of the Bone Marrow: A Case Report of Extremely Rapid Progression. Case Rep Urol. 2022;2022:6082700. doi: https://doi.org/10.1155/2022/6082700
    |
  13. Alshahwan MI, Bin Dukhi MM, Alotaibi SN, Aldarrab R, Alhefdhi NA, Al Oudah N, et al. Plasmacytoid Variant Urothelial Cell Carcinoma: A Case of a Histological Variant of Urinary Bladder Cancer With Aggressive Behavior. Cureus. 2023;15(3):e36278. doi: https://doi.org/10.7759/cureus.36278
    |
  14. Lockhart K, King S, Grant A, McLeod N, Tiu A. Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma. BJUI Compass. 2022;3(1):62-7. doi: https://doi.org/10.1002/bco2.108
    | |
  15. Lim MG, Adsay NV, Grignon DJ, Osunkoya AO. E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma. Mod Pathol. 2011;24(2):241-7. doi: https://doi.org/10.1038/modpathol.2010.187
    | |
  16. Lopez-Beltran A, Requena MJ, Montironi R, Blanca A, Cheng L. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 2009;40(7):1023-8. doi: https://doi.org/10.1016/j.humpath.2009.01.001
    | |
  17. Thomas AA, Stephenson AJ, Campbell SC, Jones JS, Hansel DE. Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol. 2009;40(1):108-16. doi: https://doi.org/10.1016/j.humpath.2008.06.022
    | |
  18. Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet. 2016;48(4):356-8. doi: https://doi.org/10.1038/ng.3503
    | |
  19. Zheng L, Chen H, Zhao J, Roy-Chowdhuri S, Kamat AM, Alhalabi O, et al. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol. 2024;148:1-6. doi: https://doi.org/10.1016/j.humpath.2024.04.012
    | |
  20. Fritsche HM, Burger M, Denzinger S, Legal W, Goebell PJ, Hartmann A. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases. J Urol. 2008;180(5):1923-7. doi: https://doi.org/10.1016/j.juro.2008.07.035
    | |
  21. Spinoit AF, Petit T, Elalouf V, Saint F, Petit J. [Signet-ring cell primitive bladder carcinoma: a rare and aggressive tumor]. Prog Urol. 2011;21(9):651-3. doi: https://doi.org/10.1016/j.purol.2011.01.001
    | |
  22. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211-4. doi: https://doi.org/10.1016/S1470-2045(10)70275-8
    | |
  23. El Ammari JE, Ahsaini M, Riyach O, El Fassi MJ, Farih MH, Hammas N, et al. Primary signet-ring cell carcinoma of the urinary bladder successfully managed with cisplatin and gemcitabine: a case report. J Med Case Rep. 2013;7:37. doi: https://doi.org/10.1186/1752-1947-7-37
    | |
  24. Li Q, Assel M, Benfante NE, Pietzak EJ, Herr HW, Donat M, et al. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. Eur Urol Focus. 2019;5(1):104-8. doi: https://doi.org/10.1016/j.euf.2017.06.013
    | |
  25. Campbell RA, Khanna A, Boorjian SA, Knorr J, Cox R, Nicholas M, et al. Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy. Clin Genitourin Cancer. 2024;22(2):157-63.e1. doi: https://doi.org/10.1016/j.clgc.2023.10.006
    | |
  26. McFadden J, Tachibana I, Adra N, Collins K, Cary C, Koch M, et al. Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy. Urol Oncol. 2024;42(3):69.e11-69.e16. doi: https://doi.org/10.1016/j.urolonc.2023.12.008
    | |

Downloads

Additional Files

Published

2026-04-30

How to Cite

1.
Yakovlev PH, Rosha LH. Plasmacytoid variant of bladder cancer is a histological factor of extremely unfavorable prognosis of recurrence-free and cancer-specific survival in organ-preserving surgical treatment of bladder cancer: clinical observations of 4 patients. Pathologia [Internet]. 2026Apr.30 [cited 2026May16];23(1):66-75. Available from: https://pat.zsmu.edu.ua/article/view/335238

Issue

Vol. 23 No. 1 (2026)

Section

Case Reports

License

Copyright (c) 2026 P. H. Yakovlev, L. H. Rosha

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Лицензия Creative Commons